Arca trims losses as leaders continue mulling merger options
BOULDER — Pre-revenue pharmaceutical firm Arca Biopharma Inc. (Nasdaq: ABIO) continued cutting costs in the second quarter of 2023, while company leaders have still yet to announce whether the company will be acquired or merged with another operator.
Arca — which has two drugs in its pipeline: COVID-19 drug candidate rNAPc2 and Gencaro (bucindolol hydrochloride), a beta-blocker and mild vasodilator that could be a potential treatment for atrial fibrillation in heart-failure patients — established a committee to weigh options for maximizing shareholder value amid a 2021 that saw it double its year-over-year losses.
Consulting firm…
THIS ARTICLE IS FOR SUBSCRIBERS ONLY
Continue reading for less than $3 per week!
Get a month of award-winning local business news, trends and insights
Access award-winning content today!



